STERIS (STE) Proxy Filing summary

Executive summary

• Fiscal 2024 saw 13.3% revenue growth to $5.14B, with net income rising to $378.2M despite a $206.4M pre-tax loss from the Dental segment divestiture and $44.4M in restructuring charges.

• Adjusted net income increased 6.7% to $877.6M, and free cash flow rose 51.4% to $620.3M.

• Dividend increased for the 18th consecutive year; strategic restructuring and divestiture actions position the company for future growth.

Voting matters and shareholder proposals

• Shareholders will vote on the re-election of 10 directors, ratification of Ernst & Young LLP as independent auditor, appointment and remuneration of Irish statutory auditor, advisory approval of executive compensation, renewal of Board authority to issue shares and opt-out of pre-emption rights, and other business.

• Board recommends voting “FOR” all proposals; most are routine under Irish law.

• Voting is by poll, with each share counting as one vote; majority required for ordinary resolutions, 75% for special resolution.

Board of directors and corporate governance

• Board consists of 10 members, 9 of whom are independent; all standing committees are fully independent.

• Board committees: Audit, Compensation and Organization Development, Nominating and Governance, Compliance and Technology.

• Annual director elections, robust self-evaluation, and strong stock ownership guidelines for directors and officers.

• No shareholder rights plan (poison pill); clawback policies in place for incentive compensation.